DelveInsight’s Methylmalonic Acidemia Report delivers an in-depth understanding of the Methylmalonic Acidemia, historical and forecasted epidemiology, and the Methylmalonic Acidemia market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Crucial Highlights from the Methylmalonic Acidemia Market Report
According to the research “Systematic literature review and meta-analysis on the epidemiology of Methylmalonic Acidemia (MMA) with an emphasis on MMA caused by methylmalonyl-CoA mutase (mut) deficiency” by Almási et al. (2019), the Meta-analysis pooled point estimates of MMA detection rates in Asia-Pacific, Europe, North America, and Middle East and North Africa (MENA) were 0.79, 1.12, 1.22, and 6.04 per 100,000 newborns.
Pipeline therapies in the Methylmalonic Acidemia are LB-001 (LogicBio Therapeutics), HST5040 (HemoShear Therapeutics), and others.
Major players involved in the Methylmalonic Acidemia market are LogicBio Therapeutics, HemoShear Therapeutics, among others.
For more information request sample @ Methylmalonic Acidemia Market
The Methylmalonic Acidemia market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Methylmalonic Acidemia market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.
Methylmalonic Acidemia: Disease Overview
Methylmalonic Acidemia (MMA) is a form of “metabolic inborn error of metabolism” that is inherited. The body is unable to adequately digest or break down certain proteins and fats (lipids) from the food eaten in this state.
Decompensation incidents, also known as metabolic crises, result from a build-up of toxic compounds and episodes of severe illness. If a metabolic crisis is not addressed, the patient can experience breathing difficulties, seizures, a stroke, a coma, and even death.
Methylmalonic Acidemia Epidemiology Segmentation
Methylmalonic Acidemia Total Incident Cases
Methylmalonic Acidemia Incident Cases Based on Mutation in Genes
Methylmalonic Acidemia Treatable Cases
Methylmalonic Acidemia Treatment Landscape
Vitamin B12 responsiveness is the primary treatment for MMA patients. A low-protein diet food plan is another treatment option for the patient. Aside from that, organ transplantation is the most effective and efficient choice.
Methylmalonic Acidemia Market
The market dynamics of Methylmalonic Acidemia (MMA) are expected to shift in the coming years due to the approval of Carbaglu and a rise in the incidence of MMA, as well as the expected launch of emerging therapies such as LB-001 (LogicBio’s GeneRide technology) and HST5040 (HemoShear Therapeutics), which are expected to boost the market in the forecasted period (2021-2030).
To learn more visit, Methylmalonic Acidemia Market Size
Methylmalonic Acidemia Pipeline Therapies and Major Companies
LB-001: LogicBio Therapeutics
HST5040: HemoShear Therapeutics
Table of Contents
Executive Summary of Methylmalonic Acidemia (MMA)
Methylmalonic Acidemia (MMA): Market Overview at a Glance
Disease Background and Overview: Methylmalonic Acidemia (MMA)
Methylmalonic Acidemia: Patient Journey
Methylmalonic Acidemia: Epidemiology and Patient Population
Methylmalonic Acidemia (MMA): Country-Wise Epidemiology
Methylmalonic Acidemia Epidemiology: United States
Methylmalonic Acidemia Epidemiology: EU–5 Countries
Methylmalonic Acidemia Epidemiology: Japan
Methylmalonic Acidemia: Treatments and Medical Practices
Methylmalonic Acidemia: Unmet Needs
Methylmalonic Acidemia: Attribute Analysis
Methylmalonic Acidemia: Marketed Therapies
Methylmalonic Acidemia: Emerging Therapies
Methylmalonic Acidemia: Key Cross Competition
Methylmalonic Acidemia (MMA): Market Size
7MM Methylmalonic Acidemia (MMA): Country-Wise Market Analysis
United States Market Size
EU5 Market Size
Japan Market Size
Methylmalonic Acidemia: Market Drivers
Methylmalonic Acidemia: Market Barriers
Reimbursement and Market Access
Get in touch with our Business executive @ Methylmalonic Acidemia Market Outlook to know more
Argininosuccinic Aciduria (ASA) Market
Get comprehensive historical and forecast analysis of Argininosuccinic Aciduria (ASA) Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Horizon Therapeutics, Acer Therapeutics, Evox Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States